| The role of tocilizumab in the management of rheumatoid arthritis. | |
| | |
MedLine Citation:
|
PMID: 22849354 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The introduction of biological treatments has improved the outlook for patients diagnosed with rheumatoid arthritis. There are now a range of different agents, targeting various pathways involved in the inflammatory process. Tocilizumab , a fully humanised anti-interleukin-6 receptor monoclonal antibody is licensed for the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis. AREAS COVERED: This article reviews and appraises the available evidence regarding the efficacy and safety of tocilizumab in rheumatoid arthritis, as identified in PubMed and Embase searches. EXPERT OPINION: Clinical trial data suggest that tocilizumab has similar efficacy both clinically and in reducing structural progression to that seen with the TNF inhibitors. Patients who might be particularly suitable for tocilizumab are those who have failed multiple TNF inhibitors, those with a high inflammatory response as part of their disease and those unable to tolerate methotrexate, given the good responses seen with monotherapy. |
| | |
Authors:
|
Zoe Ash; Paul Emery |
Related Documents
:
|
10932284 - Plasma homocysteine and mthfr c677t genotype in levodopa-treated patients with pd. 10410784 - The case for neural tissue transplantation as a treatment for parkinson's disease. 15852454 - Dementia in parkinson's disease: a post-mortem study in a population of brain donors. 11008194 - Double blinded evaluation of the effects of pallidal and subthalamic nucleus stimulatio... 9538674 - Stiff-man syndrome. results of interviews and psychologic testing. 3971754 - Radionuclide angiography in the quantitation of mitral regurgitation. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review Date: 2012-07-31 |
Journal Detail:
|
Title: Expert opinion on biological therapy Volume: 12 ISSN: 1744-7682 ISO Abbreviation: Expert Opin Biol Ther Publication Date: 2012 Sep |
Date Detail:
|
Created Date: 2012-08-14 Completed Date: 2013-01-08 Revised Date: 2013-05-20 |
Medline Journal Info:
|
Nlm Unique ID: 101125414 Medline TA: Expert Opin Biol Ther Country: England |
Other Details:
|
Languages: eng Pagination: 1277-89 Citation Subset: IM |
Affiliation:
|
University of Leeds, Leeds Institute of Molecular Medicine, Leeds Teaching Hospitals, Section of Musculoskeletal Disease, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antibodies, Monoclonal, Humanized / therapeutic use* Antirheumatic Agents / therapeutic use* Arthritis, Rheumatoid / drug therapy*, immunology Disease Progression Humans Interleukin-6 / metabolism Patient Selection Receptors, Interleukin-6 / antagonists & inhibitors, metabolism Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal, Humanized; 0/Antirheumatic Agents; 0/IL6 protein, human; 0/IL6R protein, human; 0/Interleukin-6; 0/Receptors, Interleukin-6; 0/tocilizumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Fermentation responses and in vitro radical scavenging activities of Fagopyrum esculentum.
Next Document: Environmental species sorting dominates forest-bird community assembly across scales.